PATENT CLAIM ANALYSIS

Application Number: 16131165
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-05
Patent Classification: ["514", "023000"]

Abstract:
The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.

Claim (Index 31):
The method according to  claim 1 , comprising administering empagliflozin in combination with a direct renin inhibitor, an Angiotensin-Converting Enzyme (ACE) inhibitor and/or an angiotensin II receptor blocker (ARB).

Metadata:
- Claim Count in Document: 89.0
- Percentile: 97.0
- Lexical Diversity: 1.17647
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14918713', '15918401', '14918727', '15616974', '13833097']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7651245285409259
- 35 USC 102 Novelty (BERT): 0.5495170463017839
- Combined Prediction Score: 0.7435637803170118
- Mean Citation Score: 405.76568
- Max Citation Score: 438.56375
- Similarity Product: 297.9494275024533

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test